Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future
SourceEuropean Urology Oncology, vol. 3, iss. 6, (2020), pp. 789-801
Article / Letter to editor
Display more detailsDisplay less details
European Urology Oncology
vol. vol. 3
iss. iss. 6
SubjectRadboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life Sciences
This case-based discussion describes the clinical course of a 63-yr-old patient who presented with gross hematuria and was diagnosed with a muscle-invasive bladder cancer at transurethral resection. Computed tomography revealed a locally advanced tumor, and the patient underwent neoadjuvant chemotherapy followed by open radical cystectomy with standard pelvic lymph node dissection. In a step-by-step fashion, we elaborate on diagnostic and therapeutic treatment options from two different vantage points: (1) guideline-adherent treatment with the state-of-the-art standard of care, and (2) a glimpse into the future discussing the evidence of potential additional or alternative approaches based on recent scientific advances. PATIENT SUMMARY: In this case-based discussion, we follow the clinical course of a patient with advanced bladder cancer and elaborate how the state-of-the-art treatment looks like in 2020, based on the best available evidence. This is compared with potential future treatment strategies, which may change and alternate our understanding of optimal bladder cancer care.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.